Lu Linna, Xu Shiqiong, Ge Shengfang, Shao Chunyi, Wang Zi, Weng Xuyang, Lu Wenjuan, Wu Xinhua, Fu Yao, Fan Xianqun
Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, P.R. China.
Exp Ther Med. 2017 Mar;13(3):845-850. doi: 10.3892/etm.2017.4038. Epub 2017 Jan 12.
The present study aimed to investigate the efficacy of tailored treatment for the management of scleral necrosis following pterygium surgery. A series of nine cases of scleral necrosis following pterygium excision between September 2009 and September 2012 were included. In cases where ischemia was the cause of scleral necrosis, Tenon's membrane covering (TMC) surgery was performed. For cases with surgically-induced necrotizing scleritis (SINS), systemic immunosuppressive therapy following surgical repair of the scleral defect was administered in the form of oral prednisolone (starting dose, 30-60 mg/day). Five patients with ischemic scleral necrosis received TMC postoperatively. Four patients with SINS received various doses of oral prednisolone according to their systematic immune state. All patients had successful postoperative results except one with rheumatoid arthritis, who postoperatively developed scleral patch graft melting within 2 weeks. Following aggressive immunosuppressive treatment, the scleral patch graft was saved. In conclusion, patients achieved positive results using tailored treatment according to the pathogenesis of their scleral necrosis.
本研究旨在探讨针对翼状胬肉手术后巩膜坏死的个体化治疗效果。纳入了2009年9月至2012年9月期间9例翼状胬肉切除术后发生巩膜坏死的病例。对于因缺血导致巩膜坏死的病例,进行了Tenon囊覆盖(TMC)手术。对于手术引起的坏死性巩膜炎(SINS)病例,在巩膜缺损手术修复后,以口服泼尼松龙(起始剂量,30 - 60 mg/天)的形式进行全身免疫抑制治疗。5例缺血性巩膜坏死患者术后接受了TMC手术。4例SINS患者根据其全身免疫状态接受了不同剂量的口服泼尼松龙治疗。除1例类风湿关节炎患者术后2周内发生巩膜补片移植溶解外,所有患者术后均取得成功。经过积极的免疫抑制治疗,巩膜补片移植得以挽救。总之,根据巩膜坏死的发病机制进行个体化治疗,患者取得了积极的效果。